Tigatx Inc. has been awarded up to $33.5 million in funding by the Advanced Research Projects Agency for Health and a 2-year $2 million Direct to Phase II Small Business Innovation Research grant from the National Cancer Institute.
Antiretroviral therapy effectively suppresses HIV viral loads to undetectable levels but cannot eliminate the integration of viral DNA into the host cell genome.
SK Bioscience has received approval from the Human Research Ethics Committee in Australia for a phase I/II trial of its mRNA-based Japanese encephalitis vaccine candidate, GBP-560.
Korean Research Institute of Bioscience and Biotechnology has synthesized compounds reported to be useful for the treatment of non-tuberculous mycobacterial infections.
Researchers from Inovio Pharmaceuticals Inc. described the protective effect exerted by INO-4500, a DNA vaccine produced using the Syncon technology, against lethal Lassa virus in nonhuman primates.
Orthogon Therapeutics LLC has closed an oversubscribed financing round, with funding to be used to accelerate the development of its first-in-class treatments for managing BK virus reactivation in transplant patients.
Sunshine Biopharma Inc. announced it has developed an orally active protease inhibitor that showed dose-dependent antiviral activity in mice infected with SARS-CoV-2.
In a recent publication, researchers from Colorado State University presented the development and evaluation of humanized mice as a hybrid dual-use model for testing therapeutics against both HIV and SIV infections.
RSS
